Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction

Peder L. Myhre,Muthiah Vaduganathan,Eileen O’Meara,Brian Claggett,Simon de Denus,Petr Jarolim,Inder S. Anand,Bertram Pitt,Jean L Rouleau,Scott D. Solomon,Marc A. Pfeffer,Akshay S. Desai

Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction

2020

Peder L. Myhre
Muthiah Vaduganathan
Eileen O’Meara
Brian Claggett
Simon de Denus
Petr Jarolim
Inder S. Anand
Bertram Pitt
Jean L Rouleau
Scott D. Solomon
Marc A. Pfeffer
Akshay S. Desai

Background: Spironolactone has been demonstrated to reduce heart failure (HF) hospitalization in patients with HF with preserved ejection fraction in the Americas region of the TOPCAT trial (Treatm...

Keywords:

Ejection fraction
Internal medicine
Heart failure
Cardiology
Diabetes mellitus
Spironolactone
Medicine
Uric acid
Heart failure with preserved ejection fraction
Biomarker (medicine)

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations